Cipla Ltd.

Cipla has received an approval to accept a potential investment by FIL Capital Investments (Mauritius) II, or any of its affiliate in a wholly owned subsidiary (WOS) of the company (proposed to be incorporated) to whom Cipla will be divesting its consumer healthcare business on a going-concern basis.

The board of directors at their meeting held on July 20, 2015 has approved for the same. The approval is subject to execution of binding agreements, and the transaction will be subject to relevant regulatory approvals.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.